AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system innovation in the space as drugmakers sought to avoid the common ...

AbbVie’s Rinvoq, meanwhile ... a follow-up to its 2015 infusion pump Duopa. With a non-surgical, continuous delivery system, the drug has the potential to “significantly expand use” beyond ...

The drug also represents the next generation of AbbVie's Parkinson's therapy offerings and a successor of sorts to the company's Duopa, which launched in 2015. Coverage for Medicare patients is ...

Q3 2024 Earnings Call Transcript October 30, 2024 AbbVie Inc. beats earnings expectations. Reported EPS is $3, expectations ...

AbbVie cautions that these forward-looking statements ... It can deliver high levodopa doses similar to the amount provided ...

AbbVie also sells a continuous-delivery system for Parkinson's branded as Duopa that pumps a levodopa-carbidopa gel directly into the intestinal tract for 16 hours a day. The FDA recently rejected ...

AbbVie already sells another long-acting treatment called Duopa, which delivers carbidopa and levodopa in an intestinal gel form via a gastric tube and pump, but that requires a surgical procedure ...

AbbVie Inc. discovers, develops ... Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for ...

About AbbVie Inc. and Novo Nordisk A/S AbbVie Inc. discovers ... Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine ...